Elizabeth A. Dierks
Bristol-Myers Squibb (Germany)(DE)
Publications by Year
Research Areas
Pharmacogenetics and Drug Metabolism, S100 Proteins and Annexins, Drug Transport and Resistance Mechanisms, Neuropeptides and Animal Physiology, Receptor Mechanisms and Signaling
Most-Cited Works
- A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry.(2001)
- → Studies of the Heme Coordination and Ligand Binding Properties of Soluble Guanylyl Cyclase (sGC): Characterization of Fe(II)sGC and Fe(II)sGC(CO) by Electronic Absorption and Magnetic Circular Dichroism Spectroscopies and Failure of CO To Activate the Enzyme(1995)128 cited
- → Nitric oxide (NO•), the only nitrogen monoxide redox form capable of activating soluble guanylyl cyclase(1996)105 cited
- → Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy(2021)97 cited
- → Demonstration of the Role of Scission of the Proximal Histidine−Iron Bond in the Activation of Soluble Guanylyl Cyclase through Metalloporphyrin Substitution Studies(1997)86 cited
- → Optimization of a Dihydropyrrolopyrazole Series of Transforming Growth Factor-β Type I Receptor Kinase Domain Inhibitors: Discovery of an Orally Bioavailable Transforming Growth Factor-β Receptor Type I Inhibitor as Antitumor Agent(2008)66 cited
- → Glu-320 and Asp-323 Are Determinants of the CYP4A1 Hydroxylation Regiospecificity and Resistance to Inactivation by 1-Aminobenzotriazole(1998)60 cited
- → Variable forms of soluble guanylyl cyclase: protein-ligand interactions and the issue of activation by carbon monoxide(1999)56 cited
- → Selective FPR2 Agonism Promotes a Proresolution Macrophage Phenotype and Improves Cardiac Structure-Function Post Myocardial Infarction(2021)54 cited
- → Preservation of Post-Infarction Cardiac Structure and Function via Long-Term Oral Formyl Peptide Receptor Agonist Treatment(2019)54 cited